Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years

Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.

A controlled, double blinded study to determine the safety and reactogenicity in healthy adults of a single dose of a trivalent cell-derived influenza vaccine administered by intramuscular injection.

Inclusion Criteria:

• Healthy female or male subjects aged ≧18 and ≦49 years
• Willing and able to give informed consent

Exclusion Criteria:

• Influenza vaccination of laboratory confirmed influenza infection within six months of informed consent,
• presence of any significant medical condition,
• a serious adverse reaction after a previous (influenza) vaccination,
• underlying medical conditions for which annual influenza vaccine is recommended by the Advisory Committee on Immunization Practices (ACIP),
• chronic diseases requiring long-term immunosuppressive therapy